Tonix Drops Fibromyalgia, Will Pursue PTSD Claim With Cyclobenzaprine Formulation

Failing to meet the primary endpoint of a Phase III trial of TNX-102 SL in fibromyalgia, cash-limited Tonix decides to focus on developing the drug for PTSD – which it thinks is the path of least regulatory resistance. A pair of pivotal trials is slated to commence in 2017.